Development AccelerationALTO-207 has secured financing and a regulatory path has been cleared, allowing the pivotal TRD program to accelerate by approximately one year.
Financing And InvestmentA $50 million private placement financing was announced to support the development of ALTO-207 for treatment-resistant depression.
Regulatory ApprovalThe FDA granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, validating Alto's precision-psychiatry approach.